[go: up one dir, main page]

IN2003CH00929A - - Google Patents

Download PDF

Info

Publication number
IN2003CH00929A
IN2003CH00929A IN929CH2003A IN2003CH00929A IN 2003CH00929 A IN2003CH00929 A IN 2003CH00929A IN 929CH2003 A IN929CH2003 A IN 929CH2003A IN 2003CH00929 A IN2003CH00929 A IN 2003CH00929A
Authority
IN
India
Prior art keywords
sub
pcaf
mum
compounds
useful
Prior art date
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to IN929CH2003 priority Critical patent/IN2003CH00929A/en
Priority to US10/579,219 priority patent/US7402706B2/en
Priority to EP04799059A priority patent/EP1694622B1/en
Priority to PCT/IB2004/052294 priority patent/WO2005047457A2/en
Priority to AT04799059T priority patent/ATE549309T1/en
Publication of IN2003CH00929A publication Critical patent/IN2003CH00929A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

In this patent we describe the purification of prenylated benzophenones from the fruit rinds of Garcinia species and its evaluation as an inhibitor for Histone acetyltransferases p300 and PCAF. We have found that prenylated benzophenones are potent HAT inhibitors of p300 (IC<SUB>50</SUB>-1 muM) and pCAF (IC<SUB>50</SUB>-15 muM). The inhibitors significantly repress the p300 HAT dependent transcriptional activation from in vitro assembled chromatin template but had no effect on transcription from DNA. These results suggest that the compounds could be specific to HATs. Thus these compounds should be useful as biological switching molecule for evaluating the role of p300 and PCAF in cellular functions and may be useful as new chemical entities for the development of anticancer drugs.
IN929CH2003 2003-11-13 2003-11-13 IN2003CH00929A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IN929CH2003 IN2003CH00929A (en) 2003-11-13 2003-11-13
US10/579,219 US7402706B2 (en) 2003-11-13 2004-11-04 Polyisoprenylated benzophenones and their isomers as inhibitors of histone acetyltransferases and uses thereof
EP04799059A EP1694622B1 (en) 2003-11-13 2004-11-04 Polyisoprenyl benzophenones as inhibitors of histone acetyl transferases and uses thereof
PCT/IB2004/052294 WO2005047457A2 (en) 2003-11-13 2004-11-04 Polyisoprenyl benzophenones as inhibitors of histone acetyl transferases and uses thereof
AT04799059T ATE549309T1 (en) 2003-11-13 2004-11-04 POLYISOPREVONL BENZOPHENONE AS INHIBITORS OF HISTONE ACETYLTRANSDFERASES AND APPLICATIONS THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN929CH2003 IN2003CH00929A (en) 2003-11-13 2003-11-13

Publications (1)

Publication Number Publication Date
IN2003CH00929A true IN2003CH00929A (en) 2008-10-06

Family

ID=34586954

Family Applications (1)

Application Number Title Priority Date Filing Date
IN929CH2003 IN2003CH00929A (en) 2003-11-13 2003-11-13

Country Status (5)

Country Link
US (1) US7402706B2 (en)
EP (1) EP1694622B1 (en)
AT (1) ATE549309T1 (en)
IN (1) IN2003CH00929A (en)
WO (1) WO2005047457A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022254465A1 (en) * 2021-06-02 2022-12-08 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) Small molecule modulator targeting a rare histone modification regulating adipogenesis and pharmaceutical formulation thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006520796A (en) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
JP2008524246A (en) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
JP2008540574A (en) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR057579A1 (en) * 2005-11-23 2007-12-05 Merck & Co Inc SPIROCICLICAL COMPOUNDS AS INHIBITORS OF ACETYLASE HISTONE (HDAC)
KR101005173B1 (en) * 2008-02-18 2011-01-04 인제대학교 산학협력단 Fractions Extracted from Garcinia oblongifolia and Water Compounds Isolated from Watery Waters Exhibiting Antioxidant and Cytotoxic Activity
WO2011027330A1 (en) * 2009-09-07 2011-03-10 Jawaharlal Nehru Centre For Advanced Scientific Research Inhibition of histone acetyltransferases by ctk7a and methods thereof
CN103459362B (en) * 2010-12-09 2015-11-25 英德斯生物科技私人有限公司 Garcinol and cyclodextrin complex and method thereof
WO2013148114A1 (en) * 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
GB201215942D0 (en) * 2012-09-06 2012-10-24 Glaxo Group Ltd Method of treatent
US20180369166A1 (en) * 2017-06-22 2018-12-27 Muhammed Majeed Garcinol compositions for therapeutic management of endoplasmic reticulum stress
TWI795440B (en) 2017-09-15 2023-03-11 美商佛瑪治療公司 Tetrahydro-imidazo quinoline compounds as cbp/p300 inhibitors
MX2023013508A (en) 2018-06-29 2023-12-13 Forma Therapeutics Inc INHIBITION OF CREB BINDING PROTEIN (CBP).
AR118362A1 (en) 2019-03-15 2021-09-29 Forma Therapeutics Inc CYCLIC AMP RESPONSE ELEMENT BINDING PROTEIN INHIBITION (CREB)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08259493A (en) * 1995-03-20 1996-10-08 Sugimoto Masami Anti-mrsa active substance

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022254465A1 (en) * 2021-06-02 2022-12-08 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) Small molecule modulator targeting a rare histone modification regulating adipogenesis and pharmaceutical formulation thereof

Also Published As

Publication number Publication date
US20070254961A1 (en) 2007-11-01
WO2005047457A3 (en) 2005-08-04
US7402706B2 (en) 2008-07-22
WO2005047457A2 (en) 2005-05-26
EP1694622A2 (en) 2006-08-30
EP1694622B1 (en) 2012-03-14
WO2005047457B1 (en) 2005-12-01
ATE549309T1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
IN2003CH00929A (en)
DE60137329D1 (en) COMPOSITIONS FOR THE TREATMENT OF DIABETES CONTAINING A DP IV INHIBITOR AND ANOTHER ANTI-DIABETICS
EP2003413A4 (en) OVEN MONITORING APPARATUS AND EXTRACTION PLATE CONTAINING SAME
DK1490077T3 (en) Light-protecting orally manageable composition for skin
ATE428698T1 (en) MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMMA-SECRETASE
ATE343569T1 (en) AROMATIC HYDROXAMIC ACID DERIVATIVES SUITABLE AS HDAC INHIBITORS
NO20050570L (en) New compounds, preparations and methods for the treatment of inflammatory diseases and conditions
CY2014028I1 (en) COMPOUNDS, PHARMACEUTICAL FORMS AND METHODS FOR THE TREATMENT OR PREVENTION OF ACNE ROSEPHUM
AR091405A2 (en) OMEGA-CARBOXIARIL DIFENIL UREA REPLACED WITH FLUORO AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY27993A1 (en) DERIVATIVES OF 4-PIRROLIDINO-FENIL-BENCIL ETER
ATE496109T1 (en) REACTION PRODUCTS OF MERCAPTOBENZOTHIAZOLES, MERCAPTOTHIAZOLINES AND MERCAPTOBENZIMIDAZOLES WITH EPOXIES AS LUBRICANT ADDITIVES
DE60326069D1 (en) 4- (HETEROCYCLYL) -BENZENESULFOXIMINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
NO20055741D0 (en) New chemical compounds
SE0302304D0 (en) Novel compounds
ITRN20030024A1 (en) DEVICE FOR THE COLLECTION OF BIOLOGICAL AND / OR CHEMICAL SAMPLES.
ITFI20020034A1 (en) METHOD AND DEVICE FOR THE SPECTRAL ANALYSIS OF AN ECOGRAPHIC SIGNAL
EP1879616A4 (en) SYNTHESIS OF SUPERANTIBODIES AND USE FOR THE DETECTION, PREVENTION AND TREATMENT OF DISEASE
NO20031844D0 (en) New ascorbic acid compounds, synthesis methods and their use
DE60331359D1 (en) KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
ATE497500T1 (en) CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS CONTAINING ESCITALOPRAM BASE
NO20053071L (en) Calcilitic compounds.
ATE295724T1 (en) THE DUAL INHIBITOR OF CHOLESTERYLESTER AND WAXEST SYNTHESIS AVASIMIBE FOR THE TREATMENT OF DISEASES OF THE Sebaceous Gland
IS7970A (en) PDE4 inhibitors for the treatment of lymphoma
DK1658494T3 (en) A method for in vitro titration of an NCTA and its use in a method for the evaluation and / or monitoring of a biological product production method
RU2003113761A (en) ANTI-INFLAMMATORY PRODUCT